Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Altimmune, Inc.NASDAQ: ALT

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $5K a year earlier. Trailing-twelve-month revenue was $36K.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of $1.88K (-95.4%) for the fiscal year ending Dec 2026, a slowdown from the +105.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$41K+105.0% YoY
LTMMar 2026
$36K+80.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%-65.0%+35.0 pp
1 year+105.0%-95.4%-200.4 pp
3-year CAGR—+336.8%—
5-year CAGR+418.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
41K USD
Year-over-year change
+105.0%
4-year CAGR
-68.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +80.0% is the 4th highest of 6, against a peer median of +121.1%.
ALT Competitors
Revenue for ALT and competitors
Company Period LTM YoY 3-year CAGR
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.45M USD+2889.9%-28.8%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$71.1M USD+121.1%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$69.21M USD+7.4%-8.8%
VIRVir Biotechnology, Inc.LTM Mar 2026$65.5M USD+214.0%-65.1%
IVAInventiva S.A.FY2025€4.48M EUR-51.3%-28.3%
ALTAltimmune, Inc.LTM Mar 2026$36K USD+80.0%—
GPCRStructure Therapeutics Inc.LTM Jun 2026$0 USD——
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD——
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD——
Peer median (excluding ALT) —+121.1%-28.6%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.